Novel malaria vaccines

References

• World HealthOrganization. Immunization coverage; 2020 Jul 15 [accessed 2021 Jul 01]. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage .
   Google Scholar
• Van Den Berg M, Ogutu B, Sewankambo NK, Biller-Andorno N, Tanner M. RTS,S malaria vaccine pilot studies: addressing the human realities in large-scale clinical trials. Trials. 2019;20:316. doi:10.1186/s13063-019-3391-7.
   PubMed Web of Science ®Google Scholar
• Datoo MSMNHS A, Traoré O, Rouamba T, Bellamy D, Yameogo P, Valia D, Tegneri M, Ouedraogo F, Soma R, Sawadogo S, et al. High efficacy of a low dose candidate malaria vaccine, R21 in 1 adjuvant matrix-M™, with seasonal administration to children in Burkina Faso. Lancet. 2021;397(10287):1809–1818.
   Web of Science ®Google Scholar
• Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, Kamate B, Samake Y, Guindo MA, Dolo A, et al. Safety and efficacy of PfSPZ vaccine against plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017;17(5):498–509. doi:10.1016/S1473-3099(17)30104-4.
   PubMed Web of Science ®Google Scholar
• World Health Organization. World malaria report 2020. Geneva (Switzerland): World Health Organization; 2020.
   Google Scholar
• Global technical strategy for malaria 2016-2030; Geneva (Switzerland): World Health Organization; 2015. ISBN 978 92 4 156499 1.
   Google Scholar
• Mahase E. A vaccine against malaria: five minutes with … Richard Bucala. BMJ. 2021;372:n651. doi:10.1136/bmj.n651.
   PubMedGoogle Scholar
• Baeza Garcia A, Siu E, Sun T, Exler V, Brito L, Hekele A, Otten G, Augustijn K, Janse CJ, Ulmer JB, et al. Neutralization of the plasmodium-encoded MIF ortholog confers protective immunity against malaria infection. Nat Commun. 2018;9:2714. doi:10.1038/s41467-018-05041-7.
   PubMed Web of Science ®Google Scholar
• RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31–45.
   Google Scholar
• Burkhard P, Lanar DE. Malaria vaccine based on self-assembling protein nanoparticles. Expert Rev Vaccines. 2015;14:1525–27. doi:10.1586/14760584.2015.1096781.
   PubMed Web of Science ®Google Scholar
• Schneider CG, Taylor JA, Sibilo MQ, Miura K, Mallory KL, Mann C, Karch C, Beck Z, Matyas GR, Long CA, et al. Orientation of antigen display on self-assembling protein nanoparticles influences immunogenicity. Vaccines (Basel). 2021;9. doi:10.3390/vaccines9020103.
   Web of Science ®Google Scholar
• Seth L, Bingham Ferlez KM, Kaba SA, Musser DM, Emadi S, Matyas GR, Beck Z, Alving CR, Burkhard P, Lanar DE, et al. Development of a self-assembling protein nanoparticle vaccine targeting plasmodium falciparum circumsporozoite protein delivered in three army liposome formulation adjuvants. Vaccine. 2017;35(41):5448–54. doi:10.1016/j.vaccine.2017.02.040.
   PubMed Web of Science ®Google Scholar
• Kaba SA, Karch CP, Seth L, Ferlez KMB, Storme CK, Pesavento DM, Laughlin PY, Bergmann-Leitner ES, Burkhard P, Lanar DE, et al. Self-assembling protein nanoparticles with built-in flagellin domains increases protective efficacy of a plasmodium falciparum based vaccine. Vaccine. 2018;36(6):906–14. doi:10.1016/j.vaccine.2017.12.001.
   PubMed Web of Science ®Google Scholar
• Kisalu NK, Idris AH, Weidle C, Flores-Garcia Y, Flynn BJ, Sack BK, Murphy S, Schön A, Freire E, Francica JR, et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med. 2018;24(4):408–16. doi:10.1038/nm.4512.
   PubMed Web of Science ®Google Scholar
• Tan J, Sack BK, Oyen D, Zenklusen I, Piccoli L, Barbieri S, Foglierini M, Fregni CS, Marcandalli J, Jongo S, et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat Med. 2018;24(4):401–07. doi:10.1038/nm.4513.
   PubMed Web of Science ®Google Scholar
• Noe AR, Espinosa D, Li X, Coelho-Dos-Reis JG, Funakoshi R, Giardina S, Jin H, Retallack DM, Haverstock R, Allen JR, et al. A full-length plasmodium falciparum recombinant circumsporozoite protein expressed by pseudomonas fluorescens platform as a malaria vaccine candidate. PLoS One. 2014;9(9):e107764. doi:10.1371/journal.pone.0107764.
   PubMed Web of Science ®Google Scholar
• Friedman-Klabanoff DJ, Berry AA, Travassos MA, Cox C, Zhou Y, Mo AX, Nomicos EYH, Deye GA, Pasetti MF, Laurens MB, et al. Low dose recombinant full-length circumsporozoite protein-based plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing. Vaccine. 2021;39(8):1195–200. doi:10.1016/j.vaccine.2020.12.023.
   PubMed Web of Science ®Google Scholar
• Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, Kathcart AK, Hauns KD, Komisar JL, Qabar AN, et al. Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study. J Infect Dis. 2016;214(5):762–71. doi:10.1093/infdis/jiw237.
   PubMed Web of Science ®Google Scholar
• Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci Rep. 2017;7:46621. doi:10.1038/srep46621.
   PubMed Web of Science ®Google Scholar
• Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341:1359–65. doi:10.1126/science.1241800.
   PubMed Web of Science ®Google Scholar
• Jongo SA, Church LWP, Mtoro AT, Chakravarty S, Ruben AJ, Swanson IPA, Kassim KR, Mpina M, Tumbo AM, Milando FA, et al. Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ vaccine in Tanzanian adults. Clin Infect Dis. 2019;68. doi:10.1093/cid/ciy514.
   PubMedGoogle Scholar
• Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, Gmeiner M, Campo JJ, Esen M, Ruben AJ, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542(7642):445–49. doi:10.1038/nature21060.
   PubMed Web of Science ®Google Scholar
• Jongo SA, Urbano V, Church LWP, Olotu A, Manock SR, Schindler T, Mtoro A, Kc N, Hamad A, Nyakarungu E, et al. Immunogenicity and protective efficacy of radiation-attenuated and chemo-attenuated PfSPZ vaccines in equatoguinean adults. Am J Trop Med Hyg. 2021;104(1):283–93. doi:10.4269/ajtmh.20-0435.
   PubMed Web of Science ®Google Scholar
• Kublin JG, Mikolajczak SA, Sack BK, Fishbaugher ME, Seilie A, Shelton L, VonGoedert T, Firat M, Magee S, Fritzen E, et al. Complete attenuation of genetically engineered plasmodium falciparum sporozoites in human subjects. Sci Transl Med. 2017;9(371):eaad9099. doi:10.1126/scitranslmed.aad9099.
   PubMed Web of Science ®Google Scholar
• Armistead JS, Morlais I, Mathias DK, Jardim JG, Joy J, Fridman A, Finnefrock AC, Bagchi A, Plebanski M, Scorpio DG, et al. Antibodies to a single, conserved epitope in anopheles APN1 inhibit universal transmission of plasmodium falciparum and plasmodium vivax malaria. Infect Immun. 2014;82(2):818–29. doi:10.1128/IAI.01222-13.
   PubMed Web of Science ®Google Scholar
• Bender NG, Khare P, Martinez J, Tweedell RE, Nyasembe VO, Lopez-Gutierrez B, Tripathi A, Miller D, Hamerly T, Vela EM, et al. Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen. NPJ Vaccines. 2021;6(1):49. doi:10.1038/s41541-021-00309-4.
   PubMed Web of Science ®Google Scholar
• Gale EC, Powell AE, Roth GA, Ou BS, Meany EL, Grosskopf AK, Adamska J, Picece VCTM, d’Aquino AI, Pulendran B, et al. Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2. bioRxiv. 2021. doi:10.1101/2021.03.31.437792.
   Google Scholar
• Haabeth OAW, Lohmeyer JJK, Sallets A, Blake TR, Sagiv-Barfi I, Czerwinski DK, Powell AE, Wender PA, Waymouth RM, Levy R. An mRNA SARS-CoV-2 vaccine employing a novel delivery vehicle with a TLR-9 agonist induces neutralizing antibodies and T cell memory. bioRxiv. 2021. doi:10.1101/2021.04.14.439891.
   PubMedGoogle Scholar